Skip to main content

Table 2 Change in each endpoint after FP in low and high dose treatment arms

From: Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study

 

Low dose FP

(n = 11)

High dose FP

(n = 11)

 
 

Mean (SD)

Mean (SD)

p value

change in FEV1 (L)

0.291 (0.512)

0.364 (0.356)

0.703

change in percent predicted FEV1 (%)

6.5 (11.1)

8.0 (7.1)

0.719

change in FEV1/FVC ratio after FP (%)

3.5 (4.6)

5.7 (6.1)

0.336

change in Bronchodilator response (%)

0.1 (7.8)

2.7 (5.5)

0.376

change in log RDR (%/mg)

0.955 (0.530)

0.751 (0.433)

0.335

change in log exhaled NO (ppb)

0.307 (0.259)

0.427 (0.304)

0.331

Mannitol Doubling Dose Difference

3.2 (1.8)

2.5 (1.4)

0.335

change in basement membrane thickness (μm)

-0.27 (1.08)

0.56 (1.38)

0.133

 

Median (IQR)

Median (IQR)

p value

change in Juniper ACQS

0.5 (0-1.0)

1.0 (0-1.0)

0.969

change in LPS induced TNF-alpha mRNA (Ct)

0.1 (-0.7-1.7)

0.7 (-0.4-2.1)

0.797

change in LPS induced GM-CSF mRNA (Ct)

1.7 (-1.4-3.8)

2.9 (-1.9-5.0)

0.748

change in LPS induced IL-1ra mRNA (Ct)

3.2 (2.0-4.3)

3.3 (1.3-5.7)

0.606

change in LPS induced IL-10 mRNA (Ct)

-0.6 (-1.2-1.7)

0.5 (-0.7-1.2)

0.332

change in LPS induced TNF-alpha protein (pg/mL)

830 (-3888-1302)

-2860 (-9173-2716)

0.395

change in LPS induced GM-CSF protein (pg/mL)

307 (-414-2986)

418 (-619-1154)

0.768

change in LPS induced IL-1ra protein (pg/mL)

4035 (1493-58151)

10166 (-1631-15164)

0.922

change in LPS induced IL-10 protein (pg/mL)

0.5 (-75.6-19.2)

1.3 (-44.5-79.7)

0.622

  1. SD = standard deviation, IQR = interquartile range, Ct = threshold cycle